Author:
Knych Heather K.,McKemie D.S.,Yim S.,Stanley S.D.,Arthur R.M.
Subject
Cell Biology,Clinical Biochemistry,Biochemistry,General Medicine,Analytical Chemistry
Reference23 articles.
1. Pharmacokinetic considerations in determining the terminal elimination half-lives of bisphosphonates;Lasseter;Clin. Drug Investig.,2005
2. S.H. Lee, H.S. Gong, T-H. Kim, S.Y. Park, J-H. Shin, S.W. Cho, D-W. Byun. Position Statement: Drug Holiday in Osteoporosis Treatment with Bisphosphonates in South Korea. J. Bone Metab., 22 (2015), pp. 167–174 (2015), 10.11005/jbm.2015.22.4.167.
3. Nonlinear kinetics of alendronate. Plasma protein binding and bone uptake;Lin;Drug Metab. Dispos.,1994
4. X.-L. Xu, W.-L. Gou, A.-Y. Wang, Y. Wang, Q-Y, Guo, Q. Lu, S.-B. Lu, J. Peng, Basic research and clinical applications of bisphosphonates in bone disease: what have we learned over the last 40 years? J. Transl. Med., 11 (2013), pp. 303, 10.1186/1479-5876-11-303.
5. Detection and Residence Time of Bisphosphonates in Bone of Horses;Knych;J. Vet. Diagn. Invest.,2022